# A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

> **NCT06532357** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1536 (actual)

## Conditions studied

- Migraine

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06532357
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-09
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 1536 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532357, "A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06532357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*